Page 30 - Sun Pharma

Shadow over Sun Pharma

Firm's response to governance allegations inadequate

Sudhir Valia's Sun Pharma stake helps ARC, realty business raise debt

MFs take exposure to realty arm; guarantee by investment entity gives top rating

Sun Pharma still not out of red; unsecured loan advances among key concerns

Brokerages seem concerned over the whistleblower case and domestic super-stockist distribution structure

Sun Pharma extends fall despite clarification on corporate governance issue

The stock is down 3% at Rs 442 on Tuesday, extending its 7.5% fall on Monday on the BSE.

Sun Pharma shares face turbulent times: Here is how its troubles began

Since November 26, Sun Pharma has lost Rs 133 billion in market capitalisation

Sun Pharma to bring in changes to boost investor confidence, stock falls

Investors also raised questions around loans given to 'employees and others' by the company

Sun Pharma says need more clarity from Sebi about whistle-blower complaint

Sebi has received a 150-page letter in which a whistle-blower has accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations

Sun Pharma slips 8% as Sebi starts probe; may reopen insider trading case

The stock settled 8% lower at Rs 455 on the BSE on reports that the market regulator Sebi has initiated an inquiry into the affairs of pharma major on the basis of a whistle-blower complaint.

Sun Pharma gets US FDA approval for generic Ganirelix Acetate injection

The generic version is therapeutic equivalent to Organon's Ganirelix Acetate injection, 250 mcg/0.5 ml

Sebi starts probe against Sun Pharma, to also reopen insider trading case

The whistle-blower accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations

Sebi may reopen Sun Pharma insider trading case, probe promoters' lapses

According to sources, alleged irregularities by the company's promoters and others in raising funds through FCCBs are also likely to be investigated by the watchdog

Sun Pharma: Governance issues, margin pressures expected to weigh on stock

Sun Pharma's outlook remains muted amid multiple negatives

Sun Pharma shares continue to decline

Sun Pharma stock is yet to recover from Wednesday's fall on the bourses when it hit a six-month low after a foreign brokerage firm raised concerns around corporate governance practices

Sun Pharma hits 5-month low; stock slips 7%

The stock dipped 7% to Rs 475, its lowest level since June 6, 2018 on the BSE.

Sun Pharma to acquire Japan's Pola Pharma for $1 million for derma products

Sun Pharma Monday said it will acquire Japan-based Pola Pharma for around USD 1 million to strengthen its presence in dermatology segment across the globe. The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharmaceutical Industries said in a statement. Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations. "This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us launch our speciality and generic dermatology products in the Japanese market in future," Sun Pharma Executive Vice-President Kirti Ganorkar said. Sun Pharma Japan Country Head .

Sun Pharma, subsidiary enter settlements in Modafinil antitrust litigation

The company, however, did not disclose the details of the settlement, saying the terms are confidential

Growth concerns resurface for Sun Pharma after disappointing second quarter

Analysts cut earnings estimates on muted India business growth outlook, rising expenses on specialty launches in the US

Sun Pharma hits three-month low post Q2 results; drops 10% in three days

The stock was down 5 per cent at Rs 533, trading at its lowest level since July 17, 2018, on BSE.

One-time litigation loss, slow domestic business drag Sun Pharma Q2

Company misses revenue estimates too, delivering a top line of Rs 69.37 bn, up a moderate 4.3%. Analysts had expected double-digit revenue growth for the quarter

Sun Pharma's Q2 show marred by one-offs; US growth to drive earnings

Domestic growth is likely to remain firm going ahead, while US growth led by new launches and speciality products should drive earnings